Mylan declines Senate committee request to testify about EpiPen

(Reuters) - Mylan NV has declined a U.S. Senate committee request to testify about a $465 million pending settlement to resolve charges the company underpaid government healthcare programs by misclassifying its the EpiPen emergency allergy treatment. In a Nov. 18 letter to the Senate Judiciary Committee released on Monday, Mylan said the company would not attend since government agencies had also refused to testify. Senator Chuck Grassley, who chairs the committee and had scheduled the hearing f